Future Directions in the Treatment of Osteosarcoma.
Future Directions in the Treatment of Osteosarcoma.
复制标题
DOI：
10.3390/cells10010172
复制
发表时间：
2021-01-15
期刊：
影响因子：
6
通讯作者：
Jones RL
中科院分区：
文献类型：
--
作者：
Smrke A;Anderson PM;Gulia A;Gennatas S;Huang PH;Jones RL
骨肉瘤是最常见的原发性骨肉瘤，通常在生命的第2 - 30年被诊断出来。对侵袭性和高毒性的新辅助甲氨蝶呤-阿霉素-顺铂（MAP）化疗方案的反应强烈预测结果。30多年来，骨肉瘤患者的预后没有显著变化。需要对具有高风险特征的患者进行更有效的治疗，但也需要降低所有患者的治疗相关毒性。需要预测性生物标志物来帮助通知临床医生降低或增加治疗，包括免疫治疗，并为未来的临床试验设计做出贡献。在这里，我们回顾了各种方法，以改善骨肉瘤患者的预后和生活质量，重点是结合毒性降低，免疫治疗和分子分析，以提供最有效和毒性最小的骨肉瘤治疗。
Osteosarcoma is the most common primary bone sarcoma and is often diagnosed in the 2nd–3rd decades of life. Response to the aggressive and highly toxic neoadjuvant methotrexate-doxorubicin-cisplatin (MAP) chemotherapy schedule is strongly predictive of outcome. Outcomes for patients with osteosarcoma have not significantly changed for over thirty years. There is a need for more effective treatment for patients with high risk features but also reduced treatment-related toxicity for all patients. Predictive biomarkers are needed to help inform clinicians to de-escalate or add therapy, including immune therapies, and to contribute to future clinical trial designs. Here, we review a variety of approaches to improve outcomes and quality of life for patients with osteosarcoma with a focus on incorporating toxicity reduction, immune therapy and molecular analysis to provide the most effective and least toxic osteosarcoma therapy.
登录
查看更多内容
DOI：
10.1200/jco.2014.60.0734
发表时间：
2015-07-10
期刊：
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子：
--
作者：
Bielack SS;Smeland S;Whelan JS;Marina N;Jovic G;Hook JM;Krailo MD;Gebhardt M;Pápai Z;Meyer J;Nadel H;Randall RL;Deffenbaugh C;Nagarajan R;Brennan B;Letson GD;Teot LA;Goorin A;Baumhoer D;Kager L;Werner M;Lau CC;Sundby Hall K;Gelderblom H;Meyers P;Gorlick R;Windhager R;Helmke K;Eriksson M;Hoogerbrugge PM;Schomberg P;Tunn PU;Kühne T;Jürgens H;van den Berg H;Böhling T;Picton S;Renard M;Reichardt P;Gerss J;Butterfass-Bahloul T;Morris C;Hogendoorn PC;Seddon B;Calaminus G;Michelagnoli M;Dhooge C;Sydes MR;Bernstein M;EURAMOS-1 investigators
通讯作者：
EURAMOS-1 investigators
影响因子：
3.9
作者：
Anderson, Peter M.;Hanna, Rabi
通讯作者：
Hanna, Rabi
影响因子：
3.2
作者：
Anderson PM;Meyers P;Kleinerman E;Venkatakrishnan K;Hughes DP;Herzog C;Huh W;Sutphin R;Vyas YM;Shen V;Warwick A;Yeager N;Oliva C;Wang B;Liu Y;Chou A
通讯作者：
Chou A
影响因子：
3.7
作者：
Bonvalot, S.;Gaignard, E.;Blay, J. Y.
通讯作者：
Blay, J. Y.
影响因子：
6.2
作者：
Chou, Alexander J.;Kleinerman, Eugenie S.;Krailo, Mark D.;Chen, Zhengjia;Betcher, Donna L.;Healey, John H.;Conrad, Ernest U., III;Nieder, Michael L.;Weiner, Michael A.;Wells, Robert J.;Womer, Richard B.;Meyers, Paul A.
通讯作者：
Meyers, Paul A.